Yazen expanding into metabolic care
Yazen
The key strategic point is that Yazen can turn a weight loss program into a broader metabolic care platform without rebuilding its operating model. The same app, care team, and monthly subscription already collect labs, medication data, coaching touchpoints, and now richer body composition signals from connected scales. That makes it easier to add programs for diabetes improvement, liver health, and heart risk, because those conditions are tightly linked to weight, visceral fat, and long term behavior change.
-
Withings scales measure more than body weight. They track fat percentage, muscle mass, and visceral fat, and some models add vascular age and standing heart rate. That gives Yazen a more clinical picture of whether a patient is losing harmful abdominal fat, preserving lean mass, and improving cardiovascular markers, not just getting lighter.
-
This is the same playbook used by more mature metabolic health companies. Virta built diabetes reversal around continuous remote care, connected data, and coaching, then extended that model into obesity and broader insulin resistance related conditions. Yazen is earlier, but the infrastructure pattern is similar.
-
The revenue implication is that Yazen can sell longer duration care, not just an initial GLP-1 assisted weight loss episode. A patient who reaches a target weight can stay in maintenance, keep using connected monitoring, and shift into a program framed around A1C improvement, liver risk, or cardiovascular prevention, which lifts lifetime value without a new acquisition cycle.
Over time, the winner in European obesity telehealth is likely to be the company that proves it can manage chronic metabolic disease, not just prescribe weight loss drugs. If Yazen keeps layering connected measurements onto its coaching workflow, it can move from a consumer weight loss service toward a reimbursable chronic care model with broader clinical and payer relevance.